Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Table 8 Univariate and Multivariate Variables Associated with Pazopanib-Related Non-Hypertension Cardiovascular Toxicity

	Unadjusted (univariate analysis)		Adjusted (multivariate analysis)^a
	OR	P-value	OR	P-value
Age ≥ 60 years	15.79	0.006	8.72	0.105
Male (vs. female)	0.39	0.329
Hypertension	0.90	1
Diabetes	0.93	1
Dyslipidemia	3.01	0.233
CVA/TIA^b	8.61	0.067	2.77	0.430
CAD/PAD	3.36	0.418
GFR < 60 ml/min/1.73m²	3.16	0.236
LV Dysfunction	3.21	0.327
Dysrhythmia	1.56	0.906
BMI > 30 kg/m²	0.93	1
Smoker	1.07	1
ACEi/ARB use	1.84	0.608
Beta Blocker use	1.14	1
Statin use	2.23	0.441

OR odds ratio, CI confidence interval, CVA/TIA cerebrovascular accident/transient ischemic attack, CAD/PAD coronary artery/ peripheral artery disease, GFR glomerular filtration rate, LV left ventricular, BMI body mass index, ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker
^aModel includes gender, preexisting CVA/TIA, dyslipidemia, and GFR < 60 ml/min/1.73m²
^bCVA/TIA was a perfect predictor for a non-hypertension cardiovascular event. P values based on exact logistic regression

ISSN: 2057-3804